The cost and diagnostic yield of exome sequencing for children with suspected genetic disorders: a benchmarking study
暂无分享,去创建一个
L. Lynd | C. V. van Karnebeek | A. Lehman | A. Elliott | J. Mwenifumbo | J. Friedman | S. Adam | C. du Souich | T. Nelson | Nick Dragojlovic
[1] Clara Gaff,et al. Diagnostic Impact and Cost-effectiveness of Whole-Exome Sequencing for Ambulant Children With Suspected Monogenic Conditions , 2017, JAMA pediatrics.
[2] Roland Eils,et al. Impact of clinical exomes in neurodevelopmental and neurometabolic disorders. , 2017, Molecular genetics and metabolism.
[3] Daniele Merico,et al. A microcosting and cost–consequence analysis of clinical genomic testing strategies in autism spectrum disorder , 2017, Genetics in Medicine.
[4] Gert Jan van der Wilt,et al. A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology , 2017, Genetics in Medicine.
[5] Stephen Yip,et al. The cost and cost trajectory of whole‐genome analysis guiding treatment of patients with advanced cancers , 2017, Molecular genetics & genomic medicine.
[6] Dustin Baldridge,et al. The Exome Clinic and the Role of Medical Genetics Expertise in Interpretation of Exome Sequencing Results , 2017, Genetics in Medicine.
[7] Clara Gaff,et al. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement , 2017, Genetics in Medicine.
[8] Alex Henderson,et al. De Novo Mutations in EBF3 Cause a Neurodevelopmental Syndrome. , 2017, American journal of human genetics.
[9] Rolf Schröder,et al. Clinical exome sequencing: results from 2819 samples reflecting 1000 families , 2016, European Journal of Human Genetics.
[10] Gert Jan van der Wilt,et al. Is the $1000 Genome as Near as We Think? A Cost Analysis of Next-Generation Sequencing. , 2016, Clinical chemistry.
[11] Andrea Superti-Furga,et al. Exome Sequencing and the Management of Neurometabolic Disorders. , 2016, The New England journal of medicine.
[12] Shivang Doshi,et al. Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis , 2016, The Journal of molecular diagnostics : JMD.
[13] Michael J Ackerman,et al. Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic: The Mayo Clinic Experience. , 2016, Mayo Clinic proceedings.
[14] Martha Carlson,et al. Whole Exome Sequencing in Pediatric Neurology Patients , 2016, Journal of Child Neurology.
[15] Anke M Hövels,et al. Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability , 2016, Genetics in Medicine.
[16] D. Goldstein,et al. Practical considerations in the clinical application of whole‐exome sequencing , 2016, Clinical genetics.
[17] Doug Coyle,et al. Richard Edlin, Christopher McCabe, Claire Hulme, Peter Hall, Judy Wright: Cost Effectiveness Modelling for Health Technology Assessment: A Practical Course , 2016, PharmacoEconomics.
[18] W. Chung,et al. Clinical application of whole-exome sequencing across clinical indications , 2015, Genetics in Medicine.
[19] L. Vissers,et al. Genetic studies in intellectual disability and related disorders , 2015, Nature Reviews Genetics.
[20] B. Fernandez,et al. Utility of whole‐exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care , 2015, Clinical genetics.
[21] Daniele Merico,et al. Molecular Diagnostic Yield of Chromosomal Microarray Analysis and Whole-Exome Sequencing in Children With Autism Spectrum Disorder. , 2015, JAMA.
[22] F. Zou,et al. Clinical Impact and Cost-Effectiveness of Whole Exome Sequencing as a Diagnostic Tool: A Pediatric Center’s Experience , 2015, Front. Pediatr..
[23] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[24] Xuan Yuan,et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders , 2014, Science Translational Medicine.
[25] Xiang Li,et al. Enhanced utility of family-centered diagnostic exome sequencing with inheritance model–based analysis: results from 500 unselected families with undiagnosed genetic conditions , 2014, Genetics in Medicine.
[26] Eric Vilain,et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. , 2014, JAMA.
[27] Magalie S Leduc,et al. Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.
[28] Siddharth Srivastava,et al. Clinical whole exome sequencing in child neurology practice , 2014, Annals of neurology.
[29] Véronique Geoffroy,et al. Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing , 2014, Journal of Medical Genetics.
[30] Julia Wynn,et al. The usefulness of whole-exome sequencing in routine clinical practice , 2014, Genetics in Medicine.
[31] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[32] Christian Gilissen,et al. A Post‐Hoc Comparison of the Utility of Sanger Sequencing and Exome Sequencing for the Diagnosis of Heterogeneous Diseases , 2013, Human mutation.
[33] Magalie S Leduc,et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.
[34] Dean A Regier,et al. Value for money? Array genomic hybridization for diagnostic testing for genetic causes of intellectual disability. , 2010, American journal of human genetics.
[35] Christopher McCabe,et al. Cost Effectiveness Modelling for Health Technology Assessment , 2015 .